• IO Biotech to Participate in the 2022 BIO International Convention

    Source: Nasdaq GlobeNewswire / 06 Jun 2022 08:00:00   America/New_York

    NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that the company will be participating at the 2022 BIO International Convention, taking place June 13 – 16, 2022, at the San Diego Convention Center in San Diego, California.

    The company’s chief scientific officer, Muhammad Al-Hajj, Ph.D., will also be participating in a panel discussion titled, "Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking."

    Panel details are summarized below:

    Track: Oncology
    Presentation: Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking
    Presenter: Muhammad Al-Hajj, Ph.D., IO Biotech CSO
    Date and time: Monday, June 13 at 1:00 pm local time

    About IO Biotech

    IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform. The T-win® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates.  IO Biotech is headquartered in Copenhagen, Denmark and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire).

    For further information, please visit www.iobiotech.com

    Forward-Looking Statement

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding future clinical trials, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

    Company Contact:
    Mai-Britt Zocca, Ph.D.
    President and CEO
    IO Biotech, Inc.
    mz@iobiotech.com

    Investor Contact:
    Corey Davis, Ph.D.
    LifeSci Advisors
    212-915-2577
    cdavis@lifesciadvisors.com

    Media Contact:
    Raena Mina, Ph.D.
    LifeSci Communications
    646-606-1438
    rmina@lifescicomms.com


    Primary Logo

Share on,